✦ LIBER ✦

An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder

✍ Scribed by Michihiro Takahashi; Yasushi Takita; Taro Goto; Hironobu Ichikawa; Kazuhiko Saito; Hideo Matsumoto; Yasuo Tanaka

Book ID: 108962624
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 263 KB
Volume: 65
Category: Article
ISSN: 1323-1316
DOI: 10.1111/j.1440-1819.2010.02159.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Open-label, dose-titration tolerability

Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder

✍ Michihiro Takahashi; Taro Goto; Yasushi Takita; Sang-Keun Chung; Yufeng Wang; Su 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 284 KB

Atomoxetine in children with attention-d

Atomoxetine in children with attention-deficit hyperactivity disorder with prior stimulant therapy: a prospective open-label study

✍ Paul Hammerness; Robert Doyle; Meghan Kotarski; Anna Georgiopoulos; Gagan Joshi; 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 215 KB

P.7.c.003 Maintenance of response after

P.7.c.003 Maintenance of response after open-label treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder

✍ H. Upadhyaya; J.A. Ramos-Quiroga; D. Williams; Y. Tanaka; J.R. Lane; R. Escobar; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 74 KB

Duloxetine in the treatment of adolescen

Duloxetine in the treatment of adolescents with attention deficit/hyperactivity disorder: an open-label study

✍ Javad Mahmoudi-Gharaei; Nasrin Dodangi; Mehdi Tehrani-Doost; Toktam Faghihi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

Objective The main aim of this study was to explore the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in the treatment of adolescents with attention deficit/hyperactivity disorder (ADHD). Methods Seventeen adolescents aged 11-18 years, diagnosed with ADHD, par

421. - An open label trial of venlafaxin

421. - An open label trial of venlafaxine in adults with attention deficit disorder

✍ L.A. Adler; S. Resnick; M. Kunz; O. Devinsky 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 142 KB

Atomoxetine in the Treatment of Adults w

Atomoxetine in the Treatment of Adults with Subthreshold and/or Late Onset Attention-Deficit Hyperactivity Disorder-Not Otherwise Specified (ADHD-NOS): A Prospective Open-Label 6-Week Study

✍ Craig Surman; Paul Hammerness; Carter Petty; Robert Doyle; Nicole Chu; Nitzah Ge 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 237 KB